A Mixed Methods Evaluation of Pharmacists' Readiness to Provide Long-Acting Injectable HIV Pre-exposure Prophylaxis in California.

Raiza M Beltran, Lauren A Hunter, Laura J Packel, Loriann De Martini, Ian W Holloway, Betty J Dong, Jerika Lam, Sandra I McCoy, Ayako Miyashita Ochoa
Author Information
  1. Raiza M Beltran: University of Minnesota, School of Public Health, Minneapolis, MN. ORCID
  2. Lauren A Hunter: University of California, Berkeley School of Public Health, Berkeley, CA.
  3. Laura J Packel: University of California, Berkeley School of Public Health, Berkeley, CA.
  4. Loriann De Martini: California Society of Health-System Pharmacists, Sacramento, CA.
  5. Ian W Holloway: University of California, Los Angeles Luskin School of Public Affairs, Los Angeles, CA.
  6. Betty J Dong: University of California, San Francisco School of Pharmacy, San Francisco, CA; and.
  7. Jerika Lam: Chapman University, School of Pharmacy, Irvine, CA.
  8. Sandra I McCoy: University of California, Berkeley School of Public Health, Berkeley, CA.
  9. Ayako Miyashita Ochoa: University of California, Los Angeles Luskin School of Public Affairs, Los Angeles, CA.

Abstract

BACKGROUND: Pre-exposure prophylaxis (PrEP) uptake remains low among people who could benefit, some of whom may prefer alternatives to oral PrEP, such as long-acting injectable pre-exposure prophylaxis (LAI-PrEP). We evaluated the potential for LAI-PrEP provision in pharmacies through a mixed methods study of pharmacists in California, where Senate Bill 159 enables pharmacists to independently provide oral PrEP.
METHODS: In 2022-2023, we conducted an online cross-sectional survey of California pharmacists and pharmacy students (n = 919) and in-depth interviews with pharmacists (n = 30), both of which included modules assessing attitudes about PrEP provision. Using log-binomial regression, we estimated prevalence ratios (PRs) comparing survey participants' willingness to provide LAI-PrEP by pharmacy- and individual-level characteristics. Qualitative interview data were analyzed using Rapid Qualitative Analysis to identify factors that may affect pharmacists' provision of LAI-PrEP.
RESULTS: Half of the survey participants (53%) indicated that they would be willing to administer LAI-PrEP using gluteal injection in their pharmacy. Willingness was higher among participants who worked in pharmacies that provided vaccinations or other injections (56% vs. 46%; PR: 1.2; 95% confidence interval: 1.0-1.4) and/or oral PrEP under Senate Bill 159 (65% vs. 51%; PR: 1.3; 95% confidence interval: 1.1-1.5) than among participants whose pharmacies did not. Interviewed participants reported barriers to LAI-PrEP provision, including the need for increased training and staffing, a private room for gluteal injections, better medication access, and payment for services.
CONCLUSION: Pharmacies offer a promising setting for increased LAI-PrEP access. However, pharmacists may require additional training, resources, and policy changes to make implementation feasible.

References

  1. Pharmacy (Basel). 2020 Aug 14;8(3): [PMID: 32824042]
  2. AIDS Behav. 2018 Nov;22(11):3681-3691 [PMID: 29872999]
  3. Drug Alcohol Depend. 2018 Jul 1;188:187-192 [PMID: 29778772]
  4. Curr Pharm Teach Learn. 2019 Apr;11(4):352-360 [PMID: 31040011]
  5. Psychiatry Res. 2019 Oct;280:112516 [PMID: 31437661]
  6. J Am Pharm Assoc (2003). 2022 Nov-Dec;62(6):1816-1822.e2 [PMID: 35965233]
  7. J Acquir Immune Defic Syndr. 2018 Feb 1;77(2):119-127 [PMID: 29084044]
  8. AIDS Behav. 2023 Aug;27(8):2606-2616 [PMID: 36670210]
  9. BMC Public Health. 2013 May 17;13:482 [PMID: 23679953]
  10. J Int AIDS Soc. 2023 Mar;26(3):e26077 [PMID: 36951057]
  11. Am J Pharm Educ. 2016 Apr 25;80(3):45 [PMID: 27170816]
  12. AIDS Behav. 2019 Jul;23(7):1925-1938 [PMID: 30607758]
  13. J Acquir Immune Defic Syndr. 2023 Mar 1;92(3):212-216 [PMID: 36442153]
  14. Open Forum Infect Dis. 2023 Nov 03;10(11):ofad549 [PMID: 38023549]
  15. Pharmacy (Basel). 2021 Nov 02;9(4): [PMID: 34842829]
  16. PLoS One. 2018 Nov 14;13(11):e0207372 [PMID: 30427912]
  17. J Am Pharm Assoc (2003). 2020 Jul - Aug;60(4):602-608 [PMID: 32007364]
  18. AIDS Behav. 2021 Jul;25(7):2278-2288 [PMID: 33438151]
  19. AIDS Patient Care STDS. 2020 Mar;34(3):111-123 [PMID: 32109141]
  20. AIDS Behav. 2021 Jul;25(7):2301-2315 [PMID: 33515132]
  21. J Am Pharm Assoc (2003). 2022 Jan-Feb;62(1):370-377.e3 [PMID: 34429253]
  22. Adv Ther. 2020 May;37(5):1778-1811 [PMID: 32232664]
  23. AIDS Behav. 2022 May;26(5):1377-1392 [PMID: 34669062]
  24. AIDS Patient Care STDS. 2022 Jul;36(7):254-262 [PMID: 35727647]
  25. Arch Sex Behav. 2018 Oct;47(7):2101-2107 [PMID: 28929260]
  26. Implement Sci. 2022 Oct 29;17(1):75 [PMID: 36309746]
  27. J Am Pharm Assoc (2003). 2020 Jul - Aug;60(4):e18-e24 [PMID: 32165026]
  28. J Urban Health. 2020 Oct;97(5):679-691 [PMID: 31214977]
  29. Lancet HIV. 2019 Nov;6(11):e788-e799 [PMID: 31558423]
  30. AIDS Behav. 2020 May;24(5):1452-1462 [PMID: 31654172]
  31. J Am Pharm Assoc (2003). 2022 Nov-Dec;62(6):1929-1945.e1 [PMID: 36202712]
  32. AIDS Behav. 2021 Mar;25(3):667-678 [PMID: 32910351]
  33. AIDS Behav. 2018 Apr;22(4):1184-1189 [PMID: 28913659]
  34. J Am Pharm Assoc (2003). 2023 May-Jun;63(3):742-750.e3 [PMID: 36740528]
  35. Am J Public Health. 2019 Jun;109(6):859-861 [PMID: 31067105]
  36. AIDS Care. 2021 Jun;33(6):706-711 [PMID: 32838546]

Grants

  1. T32 MH080634/NIMH NIH HHS
  2. T32MH080634/NIH HHS

MeSH Term

Humans
California
Pharmacists
Pre-Exposure Prophylaxis
Male
Female
HIV Infections
Cross-Sectional Studies
Adult
Anti-HIV Agents
Middle Aged
Surveys and Questionnaires
Attitude of Health Personnel
Injections
Young Adult

Chemicals

Anti-HIV Agents

Word Cloud

Created with Highcharts 10.0.0LAI-PrEPPrEPpharmacistsprovisionparticipants1amongmayoralpharmaciesCaliforniasurveyPre-exposureprophylaxisSenateBill159providepharmacyn=QualitativeusingglutealinjectionsvsPR:95%confidenceinterval:increasedtrainingaccessBACKGROUND:uptakeremainslowpeoplebenefitpreferalternativeslong-actinginjectablepre-exposureevaluatedpotentialmixedmethodsstudyenablesindependentlyMETHODS:2022-2023conductedonlinecross-sectionalstudents919in-depthinterviews30includedmodulesassessingattitudesUsinglog-binomialregressionestimatedprevalenceratiosPRscomparingparticipants'willingnesspharmacy-individual-levelcharacteristicsinterviewdataanalyzedRapidAnalysisidentifyfactorsaffectpharmacists'RESULTS:Half53%indicatedwillingadministerinjectionWillingnesshigherworkedprovidedvaccinations56%46%20-14and/or65%51%31-15whoseInterviewedreportedbarriersincludingneedstaffingprivateroombettermedicationpaymentservicesCONCLUSION:PharmaciesofferpromisingsettingHoweverrequireadditionalresourcespolicychangesmakeimplementationfeasibleMixedMethodsEvaluationPharmacists'ReadinessProvideLong-ActingInjectableHIVProphylaxis

Similar Articles

Cited By (1)